Buying Bio-Reference Labs (BRLI)

BRLI logoToday Bio-Reference Laboratories (BRLI) is down more than 4.5% on no news to $26.45 at the time of this writing. In a recent article I performed a detailed analysis of the company and estimated an intrinsic value of $39.23. A buy target was set at $27.46 based on a 30% margin of safety.

A quick review of the company’s fundamentals does not reveal that anything significant has changed since the time of this analysis, and I am therefore adding to my position at this price level since the stock is trading below the target buy price. For tracking purposes I am adding BRLI to the Stockodo Portfolio. Based on an allocation of 10% of a $200,000 portfolio, a total of $20,000 will be allocated to BRLI, resulting in a purchase of 750 shares.

Related: Value Investing Workflow

An entry at $26.45 represents a 32.5% margin of safety over the company’s intrinsic value. My exit target will be 15% higher than IV, which would currently be at a price of $45.11 which would represent a simple gain of just over 70% if it is realized. On the downside we will look to exit the position only if the fundamentals that prompted us to select this stock in the first place change for the worse.

Readers: What is your opinion of an investment in BRLI at these price levels? Let me know in the comments below.


One thought on “Buying Bio-Reference Labs (BRLI)

  1. I was pretty pleased to find this web site.
    I need to to thank you for ones time for this particularly fantasstic
    read!! I definitely enjjoyed every bit of it and I have you saved
    as a favorite to look at new information on your site.

Leave a Reply

Your email address will not be published. Required fields are marked *